SET Domain Bifurcated 1 (SETDB1) Antibody
383.5€ (100 µl)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
SET Domain Bifurcated 1 (SETDB1) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx011981
tested applications
ELISA, WB
Description
This gene encodes a histone methyltransferase. The encoded enzyme catalyzes the reaction of S-adenosyl-L-methionine and histone L-lysine to produce S-adenosyl-L-homocysteine and histone N (6)-methyl-L-lysine. The encoded protein likely functions in transcriptional repression.Tissue specificity: Widely expressed. High expression in testis.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Target: SET Domain Bifurcated 1 (SETDB1) Immunogen: Purified recombinant fragment of human SETDB1 expressed in E. coli. |
| Host | Mouse |
| Reactivity | Human, Mouse, Monkey |
| Assay Type | Concentration: Not determined. |
| Recommended Dilution | ELISA: 1/10000, WB: 1/500 - 1/2000. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Monoclonal |
| Conjugation | Unconjugated |
| Isotype | IgG1 |
| Observed MW | 180 kDa |
| Purification | Unpurified ascites. |
| Size 1 | 100 µl |
| Form | Liquid |
| Tested Applications | ELISA, WB |
| Buffer | Ascitic fluid containing 0.03% sodium azide. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | Q15047 |
| Gene ID | 9869 |
| Background | Antibody anti-SETDB1 |
| Status | RUO |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. |
Descripción
Related Products
Human SETDB1 (Histone-lysine N-methyltransferase SETDB1) ELISA Kit
Ver Producto
SETDB1 antibody
This gene encodes a histone methyltransferase which regulates histone methylation, gene silencing, and transcriptional repression. This gene has been identified as a target for treatment in Huntington Disease, given that gene silencing and transcription dysfunction likely play a role in the disease pathogenesis. Alternatively spliced transcript variants of this gene have been described.
Ver Producto